EP3630164
Dúlaglútíð til meðhöndlunar á langvinnum nýrnasjúkdómi
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
24.5.2018EP published:
23.8.2023EP application number:
18730908.3
EP translation filed:
23.10.2023Grant published:
15.11.2023EPO information:
European Patent Register
Max expiry date:
23.5.2038Expiry date:
23.5.2026Next due date:
31.5.2026
Title in English:
DULAGLUTIDE FOR THE TREATMENT OF CHRONIC KIDNEY DISEASELanguage of the patent:
English
Timeline
Today
24.5.2018EP application
23.8.2023EP Publication
23.10.2023Translation submitted
15.11.2023Registration published
23.5.2026Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
BOTROS, Fady TalaatAddress:
Indianapolis, Indiana 46206-6288, US
Name:
LAKSHMANAN, Mark ChandrakantAddress:
Indianapolis, Indiana 46206-6288, US
Name:
TUTTLE, Katherine RoseAddress:
Indianapolis, Indiana 46206-6288, US
Name:
ZIMMERMANN, Alan GeorgeAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762513556 PDate:
1.6.2017Country:
US
Classification
Categories:
A61K 38/26, A61K 38/28, A61K 45/06, A61P 13/12, G01N 33/68
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 19.4.2024
Expires: 23.5.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 13.5.2025
Expires: 23.5.2026
Payer: Árnason Faktor ehf.